XHKG
2120
Market cap94mUSD
Oct 09, Last price
10.92HKD
1D
4.00%
1Q
53.80%
Jan 2017
-67.88%
IPO
-77.76%
Name
Wenzhou Kangning Hospital Co Ltd
Chart & performance
P/E
12.04
P/S
0.40
EPS
0.77
Div yield, %
5.01%
Shrs. gr., 5y
-0.54%
Rev. gr., 5y
10.37%
Revenues
1.62b
-2.09%
Net income
54m
-17.09%
CFO
429m
+330.15%
Dividend
Sep 08, 20260.2081 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Wenzhou Kangning Hospital Co., Ltd. oversees and manages a broad array of healthcare facilities throughout the People's Republic of China. A core part of its mission involves providing specialized psychiatric care. The company's diverse operations also encompass real estate rental and sales, software development and IT solutions, hospital administration, forensic analysis, general medical provisions, and the retail of pharmaceutical products. Established in 1996, the organization was initially known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital before officially adopting its current name, Wenzhou Kangning Hospital Co., Ltd., in October 2014. Its principal offices are situated in Wenzhou, PRC.
Key people
Weili Guan
Executive Chairman of the Board · since 2014
Hongyue Wang
Chief Financial Officer, Executive Director · since 2014
Yi Xu
Vice General Manager · since 2014
Minjie Ye
Vice General Manager · since 2014
Feixue Zhang
Vice General Manager · since 2015
Chaoyi Zhou
Vice General Manager · since 2014
Qian Wang
Deputy General Manager · since 2014
Lianyue Wang
General Manager, Executive Director · since 2014
Secretary of the Board · since 2014
Chong Key Got
Non-Executive Director · since 2016
Xin He
Non-Executive Director · since 2014
Yang Yang
Non-Executive Director · since 2015
Yat Keung Chong
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2015
Headquarters & legal address
Wenzhou City Sheng Jin Road No. 1 Huanglong, residential area
Wenzhou, ZJ 325007
CN
Wenzhou, ZJ 325007
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||